These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26272232)

  • 21. Point-Counterpoint: CYP2C19 Genotyping for Clopidogrel.
    Larson EA; Miller NJ
    S D Med; 2017 Jan; 70(1):13-15. PubMed ID: 28810096
    [No Abstract]   [Full Text] [Related]  

  • 22. Clopidogrel-atorvastatin interaction.
    Hobbs RA; Tafreshi MJ
    Circulation; 2004 May; 109(20):e230; author reply e230. PubMed ID: 15159337
    [No Abstract]   [Full Text] [Related]  

  • 23. Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.
    Lin G; Yi L; Zhang K; Wang L; Zhang R; Xie J; Li J
    PLoS One; 2015; 10(7):e0134174. PubMed ID: 26218263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.
    Smock KJ; Saunders PJ; Rodgers GM; Johari V
    Am J Hematol; 2011 Dec; 86(12):1032-4. PubMed ID: 21812020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clopidogrel-statin interaction.
    Tantry US; Jeong YH; Gurbel PA
    Circ J; 2014; 78(3):592-4. PubMed ID: 24521731
    [No Abstract]   [Full Text] [Related]  

  • 26. Clopidogrel pharmacogenetics: Beyond candidate genes and genome-wide association studies.
    Lewis JP; Shuldiner AR
    Clin Pharmacol Ther; 2017 Mar; 101(3):323-325. PubMed ID: 27649515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clopidogrel pathway.
    Sangkuhl K; Klein TE; Altman RB
    Pharmacogenet Genomics; 2010 Jul; 20(7):463-5. PubMed ID: 20440227
    [No Abstract]   [Full Text] [Related]  

  • 28. Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.
    Peng L; Liu J; Qin L; Liu J; Xi S; Lu C; Yin T
    Thromb Res; 2017 Sep; 157():97-102. PubMed ID: 28734158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study.
    Collet JP; Hulot JS; Cuisset T; Rangé G; Cayla G; Van Belle E; Elhadad S; Rousseau H; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Barthélémy O; Beygui F; Silvain J; Vicaut E; Montalescot G;
    Eur J Clin Pharmacol; 2015 Nov; 71(11):1315-24. PubMed ID: 26265231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics of Clopidogrel: An Unresolved Issue.
    Pereira NL; Geske JB; Mayr M; Shah SH; Rihal CS
    Circ Cardiovasc Genet; 2016 Apr; 9(2):185-8. PubMed ID: 27094200
    [No Abstract]   [Full Text] [Related]  

  • 31. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).
    Wynn RL
    Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886
    [No Abstract]   [Full Text] [Related]  

  • 32. The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.
    Yang Y; Lewis JP; Hulot JS; Scott SA
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1599-617. PubMed ID: 26173871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway.
    Ford NF
    J Clin Pharmacol; 2016 Dec; 56(12):1474-1483. PubMed ID: 27196064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients.
    Amin AM; Sheau Chin L; Mohamed Noor DA; Mostafa H; Abdul Kader MASK; Kah Hay Y; Ibrahim B
    Thromb Res; 2017 Oct; 158():22-24. PubMed ID: 28802144
    [No Abstract]   [Full Text] [Related]  

  • 37. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

  • 38. Clopidogrel pharmacogenetics and its clinical implications.
    Singh M; Thapa B; Arora R
    Am J Ther; 2010; 17(3):e66-73. PubMed ID: 19636246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Farid NA; Kurihara A; Wrighton SA
    J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Joint effects of CYP2C19*2 and smoking status on clopidogrel responsiveness in patients with acute coronary syndrome.
    Peng L; Zhang L; Yang J; Wang X; Li X; Guo W; Zhang Y; Xu Q; Lu C; Yin T
    Int J Cardiol; 2015 Feb; 180():196-8. PubMed ID: 25463363
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.